Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy.

Trial Profile

Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs Catumaxomab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms CatuNeo
  • Most Recent Events

    • 10 Jul 2018 Results published in the British Journal of Cancer
    • 20 Jan 2018 Primary endpoint (Rate of macroscopic complete remissions of peritoneal carcinomatosis) has not been met, as per the results presented at the 2018 Gastrointestinal Cancers Symposium.
    • 20 Jan 2018 Final results of the study presented at the 2018 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top